Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Closed 08-28 15:00:00

47.32

-0.29

-0.61%

High47.67	Low47.10	Vol53.24M
Open47.58	D1 Closing47.61	Amplitude1.20%
Mkt Cap314.06B	Tradable Cap301.85B	Total Shares6.64B
T/O2.52B	T/O Rate0.83%	Tradable Shares6.38B
P/B4.87	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":47.32,"timestamp":1787900400000,"preClose":47.61,"halted":0,"volume":53239662,"delay":0,"changeRate":-0.0061,"floatShares":6379000000,"shares":6637000000,"eps":1.1642,"marketStatus":"Closed","change":-0.29,"latestTime":"08-28 15:00:00","open":47.58,"high":47.67,"low":47.1,"amount":2523000000,"amplitude":0.012,"askPrice":47.32,"askSize":254,"bidPrice":47.31,"bidSize":1613,"shortable":0,"etf":0,"ttmEps":1.1642,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":5,"adr":0,"adjPreClose":47.61,"symbolType":"stock","openAndCloseTimeList":[[1787880600000,1787887800000],[1787893200000,1787900400000]],"highLimit":52.37,"lowLimit":42.85,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":4.87,"roa":"--","peRate":40.645937,"roe":"8.04%","epsLYR":1.19,"committee":0.701669,"marketValue":314072000000,"turnoverRate":0.0083,"status":1,"nextConnectDate":"Northbound have stopped. The next trading day is UTC+8 2026-08-31.","hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":47.94,"timestamp":1787904513002,"preClose":48.86,"halted":0,"volume":4267783,"delay":0,"premium":"-13.01"},"floatMarketCap":301854000000},"requestUrl":"/m/hq/s/600276/tweets","defaultTab":"tweets","newsList":[{"id":"1133434643","title":"Hengrui Pharma's Interim Report Falls Flat: Legacy Blockbusters Fade as Revenue Posts First Half-Year Decline in Four Years","url":"https://stock-news.laohu8.com/highlight/detail?id=1133434643","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133434643?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:20","pubTimestamp":1787818843,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SSE: 600276) recently released its interim report for the first half of 2026, and the numbers paint a less-than-rosy picture. During the reporting period,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0012","BK0196","BK0028","01276","LU1064130708.USD","LU1997245177.USD","LU2148510915.USD","LU0359202008.SGD","LU1580142542.USD","LU0359201612.USD","LU2097828805.USD","LU2097828631.EUR","LU2097828474.EUR","LU1969619763.USD","LU1655091616.SGD","LU2289578879.USD","LU2097828557.USD","LU0359201885.HKD","LU2495084118.USD","LU0405327148.USD","LU2488822045.USD","BK0183","LU2097828714.EUR","BK0239","BK0188","LU1255011170.USD","LU1997244956.HKD","LU1997245094.SGD","LU2580892862.HKD","LU1781817850.SGD","600276","LU1064131003.USD","LU2328871848.SGD","LU1023057109.AUD","LU1328615791.USD","LU2543165471.USD","LU1820825898.SGD","LU2580892789.USD","LU1146622755.USD","LU0405327494.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106227619","title":"Singapore Sovereign Fund Boosts Stake in Chinese Drugmaker with HK$185 Million Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1106227619","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106227619?lang=en_us&edition=fundamental","pubTime":"2026-08-27 08:10","pubTimestamp":1787789429,"startTime":"0","endTime":"0","summary":"Hong Kong stock exchange disclosures have revealed a notable transaction involving a major global institutional investor and a leading Chinese pharmaceutical company.On August 21, GIC Private...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","BK0188","LU1655091616.SGD","LU0405327148.USD","LU2488822045.USD","LU2580892789.USD","BK4104","LU1997245094.SGD","BK0012","LU2097828557.USD","LU2148510915.USD","BK0196","LU1997245177.USD","LU1328615791.USD","LU1146622755.USD","BK0183","LU1064131003.USD","LU1820825898.SGD","BK0028","LU0359202008.SGD","LU0405327494.USD","LU0359201885.HKD","LU1580142542.USD","EWH","GIC","LU1997244956.HKD","LU2328871848.SGD","LU2580892862.HKD","LU1255011170.USD","LU2097828631.EUR","BK1191","LU1023057109.AUD","LU2543165471.USD","LU1781817850.SGD","LU2097828714.EUR","BK0060","LU2097828474.EUR","LU1969619763.USD","LU1064130708.USD","BK0239","LU0359201612.USD","01276","LU2289578879.USD","LU2097828805.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662444718","title":"China's Jiangsu Says it Will Support Pharmaceutical Firms' Global M&A, Licensing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662444718","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662444718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:58","pubTimestamp":1787741906,"startTime":"0","endTime":"0","summary":"UPDATE 2-China's Jiangsu says it will support pharmaceutical firms' global M&A, licensingSHANGHAI, Aug 26 (Reuters)-Chinese biotech hub Jiangsu province pledged to support pharmaceutical companies see","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL6N44N0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1255011170.USD","LU1969619763.USD","HK0000165453.HKD","LU2097828557.USD","LU0455707207.USD","LU2242644610.SGD","LU2097828474.EUR","LU1781817850.SGD","LU1655091616.SGD","KURE","BK0028","LU2097828714.EUR","01801","LU2148510915.USD","LU1997245177.USD","LU1820825898.SGD","LU0463099449.HKD","LU2097828805.USD","BK0188","LU1064130708.USD","LU2097828631.EUR","BK0183","BK0239","600276","LU0502904849.HKD","LU2328871848.SGD","BK0060","LU2580892789.USD","LU0244354667.USD","LU2488822045.USD","BK0012","LU1328615791.USD","LU1146622755.USD","BK1583","LU1997244956.HKD","BK1589","LU0326950275.SGD","LU1997245094.SGD","LU0405327494.USD","BK0196","LU1188198961.HKD","LU2580892862.HKD","LU2289578879.USD","BK1161","LU1580142542.USD","LU1064131003.USD","LU0405327148.USD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662790837","title":"JPMorgan Chase & Co.'S Short Position in H-Shares of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Increases to 3.72% on August 21 from 2.57% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790837","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790837?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:28","pubTimestamp":1787740118,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nFWN44N0FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1997245177.USD","BK0183","BK0188","LU2580892789.USD","LU1064130708.USD","BK0239","LU1146622755.USD","01276","LU0405327148.USD","LU2495084118.USD","LU0359202008.SGD","LU1655091616.SGD","LU0359201885.HKD","LU0359201612.USD","LU1023057109.AUD","BK0028","LU2543165471.USD","BK0196","LU2097828474.EUR","BK1191","BK0060","LU1781817850.SGD","LU2580892862.HKD","LU2488822045.USD","LU2097828714.EUR","LU1820825898.SGD","LU2097828557.USD","LU2328871848.SGD","LU1064131003.USD","LU2097828631.EUR","LU1969619763.USD","600276","LU1255011170.USD","LU2148510915.USD","LU1580142542.USD","LU2289578879.USD","LU1328615791.USD","LU0405327494.USD","BK0012","LU1997244956.HKD","LU1997245094.SGD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100671669","title":"Singapore's GIC Boosts Stake in Hengrui Pharma With HK$185 Million Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1100671669","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100671669?lang=en_us&edition=fundamental","pubTime":"2026-08-25 19:30","pubTimestamp":1787657435,"startTime":"0","endTime":"0","summary":"Hong Kong exchange filings reveal that on August 20, GIC Private Limited acquired an additional 3.6586 million shares of HENGRUI PHARMA (01276) at an average price of HK$50.5655 per share, bringing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997245094.SGD","BK0028","LU2580892862.HKD","BK0060","LU1064131003.USD","LU1023057109.AUD","LU0359201885.HKD","LU2580892789.USD","LU2097828631.EUR","LU1969619763.USD","LU2148510915.USD","BK0012","LU0405327494.USD","LU2488822045.USD","LU1781817850.SGD","EWH","LU0359201612.USD","BK1191","BK0239","LU2495084118.USD","01276","LU1655091616.SGD","GIC","LU2097828557.USD","LU2289578879.USD","LU1146622755.USD","BK0196","LU0359202008.SGD","LU1255011170.USD","LU2543165471.USD","LU1820825898.SGD","BK4104","BK0188","LU2097828714.EUR","LU1328615791.USD","600276","LU1997244956.HKD","LU2097828474.EUR","LU2097828805.USD","LU1064130708.USD","LU0405327148.USD","LU1580142542.USD","LU1997245177.USD","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894355","title":"HENGRUI PHARMA's HRG2010 Capsule Marketing Application Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894355","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894355?lang=en_us&edition=fundamental","pubTime":"2026-08-24 22:24","pubTimestamp":1787581455,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced that its marketing authorization application for the HRG2010 capsule has been formally accepted by China's National Medical Products Administration (NMPA),...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU2097828557.USD","LU2580892789.USD","LU0405327148.USD","LU1997244956.HKD","LU2328871848.SGD","LU2148510915.USD","LU1255011170.USD","LU2580892862.HKD","LU2097828474.EUR","LU1997245094.SGD","LU1781817850.SGD","LU1064131003.USD","LU1328615791.USD","BK0028","LU1969619763.USD","LU2097828714.EUR","LU2495084118.USD","LU1023057109.AUD","LU2097828631.EUR","LU2097828805.USD","LU1064130708.USD","BK0012","LU1580142542.USD","BK0183","LU2488822045.USD","LU1146622755.USD","LU0359201612.USD","BK0060","01276","LU0359201885.HKD","LU1997245177.USD","BK0239","BK0196","LU1655091616.SGD","LU2289578879.USD","LU0405327494.USD","BK0188","BK1191","LU1820825898.SGD","LU2543165471.USD","600276","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125046383","title":"Hengrui Pharma's Half-Year Report: Heavy Spending Fails to Drive Growth as Former Sector Leader Struggles with Revenue Without Profit Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1125046383","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125046383?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:46","pubTimestamp":1787557589,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SH: 600276) unveiled its half-year financial report in August 2026, and the mid-year scorecard, which had generated considerable market anticipation, fell...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU1655091616.SGD","LU2097828631.EUR","LU2148510915.USD","LU1781817850.SGD","BK0060","LU2097828805.USD","LU1820825898.SGD","LU2495084118.USD","BK0012","LU2543165471.USD","BK1574","LU0359201885.HKD","LU2097828474.EUR","LU2097828557.USD","LU1146622755.USD","LU1997245177.USD","600276","LU1064130708.USD","LU2488822045.USD","BK1161","LU1997245094.SGD","BK1191","BK0188","BK0196","LU1997244956.HKD","LU0405327148.USD","LU0359201612.USD","LU1064131003.USD","LU1969619763.USD","LU2097828714.EUR","LU2289578879.USD","BK0028","LU0359202008.SGD","09939","159938","LU1328615791.USD","LU2580892862.HKD","LU1255011170.USD","LU2328871848.SGD","LU0405327494.USD","BK0239","BK1515","LU1580142542.USD","LU2580892789.USD","01276","LU1023057109.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157060014","title":"Hengrui Pharma's Growth Architecture Shifts: Second Growth Engine Accelerates as Global Valuation Framework Expands","url":"https://stock-news.laohu8.com/highlight/detail?id=1157060014","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157060014?lang=en_us&edition=fundamental","pubTime":"2026-08-23 21:06","pubTimestamp":1787490393,"startTime":"0","endTime":"0","summary":"On August 19, Hengrui Pharma (01276) delivered a resilient first-half earnings report. During the period, the company recorded operating revenue of RMB 15.456 billion, with net profit attributable to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1146622755.USD","LU2097828474.EUR","BK1191","LU1064130708.USD","LU2097828631.EUR","LU2289578879.USD","BK0239","600276","BK0183","LU2580892862.HKD","LU0359201612.USD","LU1255011170.USD","LU2488822045.USD","LU1328615791.USD","BK0188","LU1997245094.SGD","LU1997244956.HKD","LU0359201885.HKD","LU1655091616.SGD","BK0196","LU0359202008.SGD","LU2328871848.SGD","LU2097828805.USD","LU1580142542.USD","BK0060","LU2495084118.USD","LU1064131003.USD","LU0405327148.USD","BK0028","LU1781817850.SGD","LU1997245177.USD","LU2097828557.USD","LU2580892789.USD","LU1820825898.SGD","BK0012","LU0405327494.USD","LU2148510915.USD","LU1023057109.AUD","LU1969619763.USD","01276","LU2097828714.EUR","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660285347","title":"Jiangsu Hengrui Pharmaceuticals- Nmpa Notice Approving Developed Class 1 Innovative Drug Licancopan Fumarate (Hrs-5965) Capsules for Marketing","url":"https://stock-news.laohu8.com/highlight/detail?id=2660285347","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660285347?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:31","pubTimestamp":1787221884,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nFWN44H0I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0359201612.USD","LU1820825898.SGD","LU1064131003.USD","BK0188","01276","LU1023057109.AUD","LU0359201885.HKD","LU1969619763.USD","LU2148510915.USD","LU1655091616.SGD","LU1146622755.USD","LU2495084118.USD","LU2097828805.USD","LU2097828714.EUR","LU2097828557.USD","LU0405327494.USD","BK0239","LU0405327148.USD","BK1191","LU1255011170.USD","LU1997244956.HKD","LU2488822045.USD","BK0028","LU2580892862.HKD","LU1328615791.USD","LU2289578879.USD","LU2580892789.USD","LU2097828631.EUR","LU0359202008.SGD","LU1781817850.SGD","LU2097828474.EUR","LU1064130708.USD","600276","LU2543165471.USD","LU1997245094.SGD","LU1997245177.USD","BK0012","LU2328871848.SGD","BK0060","BK0183","BK0196","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130698825","title":"HENGRUI PHARMA (01276) Gets Clinical Trial Approval for SHR-7012 Injection Targeting Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=1130698825","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130698825?lang=en_us&edition=fundamental","pubTime":"2026-08-20 18:26","pubTimestamp":1787221594,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) has announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2580892862.HKD","BK1191","LU1064130708.USD","LU0405327148.USD","BMED","IBBQ","LU2148510915.USD","BK0239","LU1023057109.AUD","LU1997245094.SGD","IBBJ","LU2543165471.USD","LU0359202008.SGD","BK0196","LU1997245177.USD","LU1580142542.USD","LU2580892789.USD","LU0359201612.USD","LU1328615791.USD","LU0405327494.USD","PSYK","BK0012","LU0359201885.HKD","LU2097828805.USD","01276","LU2495084118.USD","LU1064131003.USD","BK0183","LU1255011170.USD","LU2488822045.USD","BK0060","LU2097828557.USD","600276","LU2328871848.SGD","LU2097828474.EUR","LU2289578879.USD","LU1997244956.HKD","LU1969619763.USD","LU1781817850.SGD","BK0028","LU1146622755.USD","BK0188","LU1820825898.SGD","LU2097828631.EUR","LU2097828714.EUR","LU1655091616.SGD","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660402406","title":"Jiangsu Hengrui Pharmaceuticals Says Chinese Regulator Approved Hrs-5965 Capsule for Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2660402406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660402406?lang=en_us&edition=fundamental","pubTime":"2026-08-20 16:43","pubTimestamp":1787215399,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL4N44H0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1997245094.SGD","BK0028","LU2580892862.HKD","BK0060","LU1064131003.USD","LU2580892789.USD","LU2097828631.EUR","LU1969619763.USD","LU2148510915.USD","BK0012","LU0405327494.USD","LU2488822045.USD","LU1781817850.SGD","BK0239","LU2495084118.USD","LU1655091616.SGD","LU2097828557.USD","LU2289578879.USD","LU1146622755.USD","BK0196","LU1255011170.USD","LU1820825898.SGD","BK0188","LU2097828714.EUR","LU1328615791.USD","600276","LU1997244956.HKD","LU2097828474.EUR","LU2097828805.USD","LU1064130708.USD","LU0405327148.USD","LU1580142542.USD","LU1997245177.USD","LU2328871848.SGD","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660118408","title":"Jiangsu Hengrui Hong Kong Shares Hit Record Low on Quarterly Profit Miss","url":"https://stock-news.laohu8.com/highlight/detail?id=2660118408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660118408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:20","pubTimestamp":1787199653,"startTime":"0","endTime":"0","summary":"BUZZ-Jiangsu Hengrui Hong Kong shares hit record low on quarterly profit miss** Hong Kong shares of Jiangsu Hengrui Pharmaceuticals1276.HKdrop 11.2% to HK$48.8, record low since debut in May 2025** St","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nL1N44H03J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","600276","LU2097828805.USD","LU0359201612.USD","LU1328615791.USD","01276","LU1820825898.SGD","LU2488822045.USD","LU2097828631.EUR","LU0359202008.SGD","BK1191","LU2289578879.USD","LU1781817850.SGD","BK0239","LU1580142542.USD","LU2148510915.USD","LU2097828557.USD","LU2580892789.USD","LU0405327148.USD","LU2328871848.SGD","LU2097828474.EUR","LU2495084118.USD","LU2543165471.USD","BK0060","LU0359201885.HKD","LU1997244956.HKD","BK0028","BK0188","LU1146622755.USD","BK0183","BK0196","LU1023057109.AUD","LU2580892862.HKD","LU1064130708.USD","LU1064131003.USD","LU1655091616.SGD","LU1997245094.SGD","LU2097828714.EUR","LU0405327494.USD","BK0012","LU1997245177.USD","LU1255011170.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185153566","title":"Hengrui Pharma Appoints Tian Fei as New Board Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1185153566","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185153566?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:22","pubTimestamp":1787149332,"startTime":"0","endTime":"0","summary":"Hengrui Pharma (01276) has announced a key executive change, with the appointment of Tian Fei as the company's new Board Secretary.The decision was formally ratified during the fourth meeting of the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997244956.HKD","LU1146622755.USD","LU2543165471.USD","LU2097828714.EUR","BK0239","LU2289578879.USD","LU2097828805.USD","LU2580892862.HKD","BK0012","BK0188","LU2328871848.SGD","BK0028","LU1781817850.SGD","BK1191","LU1969619763.USD","LU1064130708.USD","LU1023057109.AUD","LU0405327494.USD","LU1255011170.USD","LU1580142542.USD","LU1328615791.USD","LU1997245177.USD","LU2097828474.EUR","LU1820825898.SGD","LU2495084118.USD","BK0183","LU1064131003.USD","LU2097828631.EUR","600276","BK0060","LU2580892789.USD","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","LU1997245094.SGD","LU2097828557.USD","LU2148510915.USD","LU2488822045.USD","LU1655091616.SGD","BK0196","LU0405327148.USD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660390429","title":"Hengrui Pharma Launches RMB 1 Billion-RMB 2 Billion A-Share Buyback, Caps Price at RMB 81.78","url":"https://stock-news.laohu8.com/highlight/detail?id=2660390429","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660390429?lang=en_us&edition=fundamental","pubTime":"2026-08-19 22:15","pubTimestamp":1787148910,"startTime":"0","endTime":"0","summary":"Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78Jiangsu Hengrui launched an A-share buyback plan of RMB 1-2 billion via centralized price bidding.Repurchase","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL5rgRfP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","LU2148510915.USD","LU1146622755.USD","LU2289578879.USD","LU1997245094.SGD","LU1820825898.SGD","LU2097828474.EUR","LU2097828714.EUR","BK0188","LU1580142542.USD","LU1997245177.USD","LU1064130708.USD","LU2495084118.USD","LU1255011170.USD","LU0405327494.USD","LU1969619763.USD","LU2580892862.HKD","BK0183","LU1655091616.SGD","LU2097828557.USD","LU2580892789.USD","BK0196","LU2097828631.EUR","LU1064131003.USD","LU1997244956.HKD","LU1328615791.USD","BK0028","600276","BK0012","BK0239","LU2097828805.USD","LU2328871848.SGD","BK0060","LU1781817850.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139277418","title":"HENGRUI PHARMA Proposes New H-Share Incentive Scheme for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1139277418","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139277418?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:52","pubTimestamp":1787147541,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) announced that on August 19, 2026, its board has resolved to recommend the adoption of the 2026 H-Share Share Plan.The plan will take effect upon approval at the upcoming first extraordinary general meeting of the company in 2026.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU2580892789.USD","BK1191","LU2580892862.HKD","LU1255011170.USD","LU2289578879.USD","LU1328615791.USD","BK0060","LU0405327148.USD","LU1997244956.HKD","BK0012","LU2495084118.USD","LU1023057109.AUD","LU2097828474.EUR","LU2097828805.USD","LU1997245177.USD","LU1146622755.USD","LU2328871848.SGD","LU1969619763.USD","LU0359201612.USD","600276","LU1781817850.SGD","LU2543165471.USD","LU2097828714.EUR","BK0183","LU0359201885.HKD","LU2148510915.USD","BK0196","LU0359202008.SGD","BK0188","LU1064131003.USD","LU2097828557.USD","LU2097828631.EUR","LU1064130708.USD","LU1580142542.USD","BK0028","LU1997245094.SGD","BK0239","LU0405327494.USD","LU1655091616.SGD","LU1820825898.SGD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660316426","title":"Hengrui Pharma FY26 H1 Profit Attributable to Owners Rises 0.3% to RMB 4.47 Billion; Revenue Falls 1.9% to RMB 15.46 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2660316426","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660316426?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:41","pubTimestamp":1787146899,"startTime":"0","endTime":"0","summary":"Hengrui Pharma FY26 H1 profit attributable to owners rises 0.3% to RMB 4.47 billion; revenue falls 1.9% to RMB 15.46 billionJiangsu Hengrui Medicine posted revenue of RMB 15.46 billion, down 1.9% year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL35gKSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1261432733.SGD","BK4007","BK4532","LU1074936037.SGD","LU0306806265.USD","LU1032466523.USD","LU0225771236.USD","LU1718418525.SGD","LU1868836757.USD","FTXH","LU2580892862.HKD","LU1670711040.USD","LU2097828474.EUR","BMY","BK0239","BK0028","LU1983299246.USD","LU0237698245.USD","LU1868837136.USD","LU2596442595.SGD","BK4581","BK0188","BK4559","IE00B2B36J28.USD","LU1093756325.SGD","BK0012","LU1781817850.SGD","BK4588","IHE","LU1093756168.USD","600276","LU2125154778.USD","LU0114720955.EUR","LU0868494617.USD","LU2097828557.USD","LU0267386448.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1670711123.USD","LU2125154935.USD","LU2495084118.USD","LU1670710661.SGD","LU0321505439.SGD","LU1969619763.USD","BK0060","LU1997245177.USD","LU0432979614.USD","LU1064131003.USD","LU2097828714.EUR","LU2242652126.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178000037","title":"Hengrui Pharma's First-Half Results Unveil Strategic Shifts: From Innovative Drugs to NewCo Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1178000037","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178000037?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:08","pubTimestamp":1787141307,"startTime":"0","endTime":"0","summary":"On August 19, Hengrui Pharma (01276) released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of RMB 15.456 billion, with product sales revenue of RMB...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","LU0359201885.HKD","LU1820825898.SGD","LU2289578879.USD","LU2580892862.HKD","BK1574","01276","LU2488822045.USD","LU2097828474.EUR","LU2097828631.EUR","LU2097828714.EUR","BK0239","BK0028","159992","LU1146622755.USD","06978","LU0359202008.SGD","LU1655091616.SGD","LU2097828805.USD","LU2148510915.USD","LU2580892789.USD","BK0188","LU1328615791.USD","IBBQ","LU1781817850.SGD","BK0012","MEDX","LU2543165471.USD","600276","BK0196","BK1161","LU2097828557.USD","LU0359201612.USD","LU2495084118.USD","BK1191","LU0405327494.USD","LU1969619763.USD","BK0060","LNGR","LU2328871848.SGD","LU1023057109.AUD","LU1997245177.USD","LU1580142542.USD","BK0183","LU1997244956.HKD","LU1255011170.USD","LU1997245094.SGD","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440424","title":"Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660440424?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:46","pubTimestamp":1787140019,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA1XZLBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","BK0239","LU2495084118.USD","LU1781817850.SGD","LU1997244956.HKD","BK0028","LU1997245094.SGD","LU2097828631.EUR","BK0183","LU1064130708.USD","LU2580892862.HKD","BK0012","LU2580892789.USD","LU2148510915.USD","LU0405327148.USD","LU1655091616.SGD","LU2097828805.USD","LU1328615791.USD","LU2097828557.USD","LU2328871848.SGD","BK0188","LU2097828714.EUR","LU1255011170.USD","600276","BK0060","LU1820825898.SGD","LU1969619763.USD","LU1146622755.USD","LU1064131003.USD","LU1997245177.USD","LU2488822045.USD","LU2289578879.USD","LU1580142542.USD","LU0405327494.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440185","title":"Jiangsu Hengrui Pharmaceuticals Says it Plans to Buy Back Co A-Shares Worth 1-2 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440185","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660440185?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:42","pubTimestamp":1787139778,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4N44G0YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2580892789.USD","LU1328615791.USD","LU1064131003.USD","LU0405327148.USD","LU1146622755.USD","BK0239","BK0060","LU2097828631.EUR","BK0012","LU1997245094.SGD","LU2495084118.USD","LU2289578879.USD","LU1580142542.USD","LU2580892862.HKD","BK0196","LU1064130708.USD","LU1969619763.USD","LU1997245177.USD","LU2097828714.EUR","LU1655091616.SGD","LU1997244956.HKD","LU2488822045.USD","LU0405327494.USD","BK0188","BK0028","LU2148510915.USD","LU2097828805.USD","600276","BK0183","LU2097828474.EUR","LU1820825898.SGD","LU1255011170.USD","LU2328871848.SGD","LU2097828557.USD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660744072","title":"China's Top Drugmaker Hengrui Reports Slight Rise in H1 Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2660744072","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660744072?lang=en_us&edition=fundamental","pubTime":"2026-08-19 19:39","pubTimestamp":1787139586,"startTime":"0","endTime":"0","summary":"China's top drugmaker Hengrui reports slight rise in H1 profitBEIJING, Aug 19 (Reuters)-Jiangsu Hengrui Pharmaceuticals600276.SS, China's biggest drugmaker by market value, reported a 0.34% rise in its first-half net profit on Wednesday, according to a filing to the Shanghai Stock Exchange.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL4N44G0YP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","BK0188","LU1655091616.SGD","LU0405327148.USD","LU2488822045.USD","LU2580892789.USD","LU1997245094.SGD","BK0012","LU2097828557.USD","LU2148510915.USD","BK0196","LU1997245177.USD","LU1146622755.USD","BK0183","LU1064131003.USD","LU1820825898.SGD","BK0028","LU0405327494.USD","LU1580142542.USD","LU1997244956.HKD","LU2328871848.SGD","LU2580892862.HKD","LU1255011170.USD","LU2097828631.EUR","LU1781817850.SGD","LU2097828714.EUR","BK0060","LU2097828474.EUR","600276","LU1969619763.USD","LU1064130708.USD","BK0239","LU2289578879.USD","LU2097828805.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787940442362,"stockEarnings":[{"period":"1week","weight":-0.0088},{"period":"1month","weight":-0.1219},{"period":"3month","weight":-0.0572},{"period":"6month","weight":-0.1599},{"period":"1year","weight":-0.2462},{"period":"ytd","weight":-0.2024}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.0323},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0283},{"period":"ytd","weight":-0.0042}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"539148人(较上一季度增加17.64%)","perCapita":"11831股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":"　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是注射用卡瑞利珠单抗、羟乙磺酸达尔西利片、瑞维鲁胺片、海曲泊帕乙醇胺片、脯氨酸恒格列净片、碘佛醇注射液。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction